Am J Psychiatry 157:1141-1149, July 2000
© 2000 American Psychiatric Association
Ionotropic Glutamate Receptors and Expression of N-Methyl-D-Aspartate Receptor Subunits in Subregions of Human Hippocampus: Effects of Schizophrenia
Xue-Min Gao, , M.D.,
Kazuo Sakai, , M.D.,
Rosalinda C. Roberts, , Ph.D.,
Robert R. Conley, , M.D.,
Brian Dean, , Ph.D., and
Carol A. Tamminga, , M.D.
OBJECTIVE: Multiple quantifiable biologic abnormalities have been localized to the hippocampus in schizophrenia. Alterations in glutamate-mediated transmission at N-methyl-D-aspartic acid (NMDA)-sensitive receptors in hippocampus have been implicated in the pathophysiology of the illness. The authors tested the hypothesis that glutamatergic transmission within and efferent from hippocampus is altered in schizophrenia.METHOD: The authors analyzed postmortem hippocampal tissue from individuals with schizophrenia and from healthy individuals. The tissue samples had been collected by two brain tissue banks, one in Maryland and the other in Melbourne, Australia. lonotropic receptor binding for the NMDA, kainate, and 3H-amino-3-hydroxy-5-methylisoxazol-4-propionate (AMPA) receptors was quantified by using usual radioligand techniques. In situ hybridization autoradiography was used to quantify mRNA for the NMDA receptor subunits NR1, NR2A, and NR2B.RESULTS: Ligand binding to the ionotropic glutamate receptors (NMDA, kainate, and AMPA) did not differ significantly overall or in any subregion between the schizophrenia tissue and the healthy comparison tissue. The only exception was AMPA receptor binding in hippocampal subregion CA2, which was slightly but significantly less in schizophrenia. However, the level of mRNA for the NMDA receptor subunits NR1 and NR2B was significantly different between groups; in several hippocampal subregions, the level of NR1 mRNA was lower and the level of NR2B mRNA higher in schizophrenia.CONCLUSIONS: Because the NR1 subunit of the NMDA receptor is critical to full receptor activity, a reduction of NR1 in hippocampus in schizophrenia suggests a functional impairment in glutamatergic transmission at the NMDA receptor, resulting in reduced glutamatergic transmission within and possibly efferent from the hippocampus in schizophrenia. This defect could underlie a hypoglutamatergic state in regions of limbic cortex, consistent with published results from other lines of research in schizophrenia.
This article has been cited by other articles:
|
|
|
|
 
U. Meyer, J. Feldon, and B. K. Yee
A Review of the Fetal Brain Cytokine Imbalance Hypothesis of Schizophrenia
Schizophr Bull,
September 1, 2009;
35(5):
959 - 972.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ghose, K. A. Gleason, B. W. Potts, K. Lewis-Amezcua, and C. A. Tamminga
Differential Expression of Metabotropic Glutamate Receptors 2 and 3 in Schizophrenia: A Mechanism for Antipsychotic Drug Action?
Am J Psychiatry,
July 1, 2009;
166(7):
812 - 820.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Stone, P. D. Morrison, and L. S. Pilowsky
Review: Glutamate and dopamine dysregulation in schizophrenia a synthesis and selective review
J Psychopharmacol,
June 1, 2007;
21(4):
440 - 452.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Akbarian, M. G. Ruehl, E. Bliven, L. A. Luiz, A. C. Peranelli, S. P. Baker, R. C. Roberts, W. E. Bunney Jr, R. C. Conley, E. G. Jones, et al.
Chromatin Alterations Associated With Down-regulated Metabolic Gene Expression in the Prefrontal Cortex of Subjects With Schizophrenia
Arch Gen Psychiatry,
August 1, 2005;
62(8):
829 - 840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Centonze, A. Usiello, C. Costa, B. Picconi, E. Erbs, G. Bernardi, E. Borrelli, and P. Calabresi
Chronic Haloperidol Promotes Corticostriatal Long-Term Potentiation by Targeting Dopamine D2L Receptors
J. Neurosci.,
September 22, 2004;
24(38):
8214 - 8222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Pei, F. J. S. Lee, A. Moszczynska, B. Vukusic, and F. Liu
Regulation of Dopamine D1 Receptor Function by Physical Interaction with the NMDA Receptors
J. Neurosci.,
February 4, 2004;
24(5):
1149 - 1158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. I. Tarazi, R. J. Baldessarini, N. S. Kula, and K. Zhang
Long-Term Effects of Olanzapine, Risperidone, and Quetiapine on Ionotropic Glutamate Receptor Types: Implications for Antipsychotic Drug Treatment
J. Pharmacol. Exp. Ther.,
September 1, 2003;
306(3):
1145 - 1151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Clinton, V. Haroutunian, K. L. Davis, and J. H. Meador-Woodruff
Altered Transcript Expression of NMDA Receptor-Associated Postsynaptic Proteins in the Thalamus of Subjects With Schizophrenia
Am J Psychiatry,
June 1, 2003;
160(6):
1100 - 1109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Hemby, S. D. Ginsberg, B. Brunk, S. E. Arnold, J. Q. Trojanowski, and J. H. Eberwine
Gene Expression Profile for Schizophrenia: Discrete Neuron Transcription Patterns in the Entorhinal Cortex
Arch Gen Psychiatry,
July 1, 2002;
59(7):
631 - 640.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B Dean
Understanding the pathology of schizophrenia: recent advances from the study of the molecular architecture of postmortem CNS tissue
Postgrad. Med. J.,
March 1, 2002;
78(917):
142 - 148.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Lahti, H. H. Holcomb, D. R. Medoff, M. A. Weiler, C. A. Tamminga, and W. T. Carpenter Jr.
Abnormal Patterns of Regional Cerebral Blood Flow in Schizophrenia With Primary Negative Symptoms During an Effortful Auditory Recognition Task
Am J Psychiatry,
November 1, 2001;
158(11):
1797 - 1808.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R. Gainetdinov, A. R. Mohn, L. M. Bohn, and M. G. Caron
Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter
PNAS,
September 25, 2001;
98(20):
11047 - 11054.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2000
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
